Abstract (italian): Alcune start-up tecnologiche cercano opportunità di crescita grazie alla partnership con grandi aziende di dispositivi medici a base di nanotecnologia, per ridurre i costi nelle catene di approvvigionamento. Incorporando le nanotecnologie nei loro prodotti, produttori di apparecchiature originali (OEM) possono ottimizzare la loro supply chain riducendo i costi. La nanotecnologia permette ai produttori di creare prodotti differenziati di alta precisione che migliorano la qualità complessiva della vita dei pazienti.
London – December 22, 2016 – Nanotechnology-based medical devices reduce costs across supply and demand value chains, as they firmly place the bargaining power in the hands of large medical device manufacturing companies. By incorporating nanotechnology into their products, original equipment manufacturers (OEMs) can streamline their supply chain and eliminate business units that hurt their margin. Nanotechnology enables manufacturers to create differentiated, highly precise products that improve the overall quality of life for patients, which opens up the scope for their commercialization.
“Owing to the significant commercialisation potential of nano-materials, large medical device companies have partnered with university spin-offs and research institutes to co-create solutions that improve the effectiveness of therapies,” said Frost & Sullivan TechVision Industry Analyst Arjunvasan Ambigapathy. “Researchers particularly focus on developing products for high-growth medical device sectors such as wearables, point-of-care diagnostics, advanced wound care, and drug delivery systems, targeting conditions other than cancer.”
Nanotechnology to Achieve Cost Efficiencies within Global Medical Devices Value Chain is part of the TechVision(Microelectronics) Growth Partnership Service program. The study details technology developments in the major medical device segments of drug delivery systems, in vivo imaging, medical implants and in vitro diagnostics. It also evaluates the outcomes of strategic partnerships with start-ups and research institutions, and explores investment opportunities in nanotechnology research programs.
Click here for complimentary access to more information on this analysis and to register for a Growth Strategy Dialogue, a free interactive briefing with Frost & Sullivan’s thought leaders.
There are few impediments to the rapid commercialisation and adoption of nanotechnology during development of medical devices. Even the challenges inherent in the scaling up of nanocoating technologies and nano-functionalisation of surfaces for the improved performance of devices are almost negligible.
“Meanwhile, initiatives by global regulatory agencies to encourage the use of nanotechnology in medical devices are likely to have a big impact on the large-scale commercialication of nano-based medical devices,” noted Ambigapathy.
Overall, companies that can out-innovate their peers and are quick to form strategic partnerships with industry majors are best poised to succeed early.